<?xml version="1.0" encoding="UTF-8"?>
<p id="Par39">From a patient, healthcare, and economic perspective, shorter treatment duration is obviously preferred and overtreatment should be prevented. In current clinical practice, an increasing number of physicians discontinue treatment on an individual basis in patients achieving tumour response, in case of severe toxicity, or on patients' request [
 <xref ref-type="bibr" rid="CR25">25</xref>]. However, substantial evidence about the safety of early discontinuation of PD-1 blockade is lacking. Therefore, a nationwide prospective interventional study has been initiated to generate evidence on early discontinuation of first-line PD-1 blockade in patients with advanced and metastatic melanoma. For feasible implementation in clinical practice, the study has been designed according to patients' wishes and procedures of daily clinical practice.
</p>
